134 related articles for article (PubMed ID: 22762038)
1. Antifungal efficacy of natamycin in experimental fusarium solani keratitis.
Dong XH; Gao WJ; He XP
Int J Ophthalmol; 2012; 5(2):143-6. PubMed ID: 22762038
[TBL] [Abstract][Full Text] [Related]
2. Rabbit Fungal Keratitis Model of Fusarium solani Tested Against Three Commercially Available Antifungal Drugs.
Aung TT; Chor WHJ; Lynn MN; Chan ASY; Tan DTH; Beuerman RW
Eye Contact Lens; 2020 Sep; 46(5):274-280. PubMed ID: 32134799
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intrastromal injection of 5% natamycin in experimental fusarium keratitis.
Mimouni M; Tam G; Paitan Y; Kidron D; Segev F
J Ocul Pharmacol Ther; 2014 Sep; 30(7):543-7. PubMed ID: 24919100
[TBL] [Abstract][Full Text] [Related]
4. Effect of topical 0.5% povidone-iodine compared to 5% natamycin in fungal keratitis caused by Fusarium solani in a rabbit model: a pilot study.
Oliveira LA; Takata TT; Shiguematsu AI; Melo Júnior LA; Gompertz OF; Sousa LB; Mannis MJ
Arq Bras Oftalmol; 2008; 71(6):860-4. PubMed ID: 19169521
[TBL] [Abstract][Full Text] [Related]
5. Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against
Sha X; Chan L; Fan X; Guo P; Chen T; Liu L; Zhong J
Int J Nanomedicine; 2022; 17():1463-1478. PubMed ID: 35378880
[TBL] [Abstract][Full Text] [Related]
6. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic response time of topical voriconazole 1% and intrastromal voriconazole 0.05% versus topical natamycin 5% monotherapy in Fusarium keratitis in rabbit.
Edwar L; Janna YM; Rozaliyani A; Louisa M
Mycoses; 2020 Oct; 63(10):1128-1132. PubMed ID: 32780874
[TBL] [Abstract][Full Text] [Related]
8. Antifungal Efficacy of Luliconazole in an Experimental Rabbit Model of Fungal Keratitis Caused by Fusarium solani.
Arimoto S; Inagaki K; Todokoro D; Suzuki T; Makimura K; Ishino T
Mycopathologia; 2023 Oct; 188(5):775-782. PubMed ID: 37603230
[TBL] [Abstract][Full Text] [Related]
9. Niosomes: Do They Increase the Potency of Topical Natamycin Ketorolac Formula in Treating Aspergillus Keratitis? An Experimental Study.
El-Mofty HM; El-Nabarawi MA; Abd El Rehem RT; Teaima MH; Abary MYS; Salah M; Lotfy NM
J Ocul Pharmacol Ther; 2020 Sep; 36(7):545-554. PubMed ID: 32357092
[No Abstract] [Full Text] [Related]
10. Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.
Yavas GF; Oztürk F; Küsbeci T; Cetinkaya Z; Ermis SS; Kiraz N; Inan UU
Graefes Arch Clin Exp Ophthalmol; 2008 Feb; 246(2):275-9. PubMed ID: 17912543
[TBL] [Abstract][Full Text] [Related]
11. Medical interventions for fungal keratitis.
FlorCruz NV; Evans JR
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD004241. PubMed ID: 25855311
[TBL] [Abstract][Full Text] [Related]
12. [Prolonged topical natamycin 5 % therapy before and after keratoplasty for Fusarium keratitis].
Cvetkova N; Köstler J; Prahs P; Helbig H; Dietrich-Ntoukas T
Ophthalmologe; 2016 May; 113(5):420-4. PubMed ID: 26205744
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effect of Intrastromal Voriconazole, Topical Voriconazole, and Topical Natamycin on Fusarium Keratitis in Rabbit.
Nejabat M; Yaqubi N; Khosravi A; Zomorodian K; Ashraf MJ; Salouti R
J Ophthalmol; 2016; 2016():8692830. PubMed ID: 27298734
[TBL] [Abstract][Full Text] [Related]
14. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis.
Kalavathy CM; Parmar P; Kaliamurthy J; Philip VR; Ramalingam MD; Jesudasan CA; Thomas PA
Cornea; 2005 May; 24(4):449-52. PubMed ID: 15829804
[TBL] [Abstract][Full Text] [Related]
15. [Natamycin (pimaricin) in the treatment of experimental keratomycosis].
Behrens-Baumann W; Klinge B
Fortschr Ophthalmol; 1990; 87(3):237-40. PubMed ID: 2376371
[TBL] [Abstract][Full Text] [Related]
16. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial.
Sharma S; Das S; Virdi A; Fernandes M; Sahu SK; Kumar Koday N; Ali MH; Garg P; Motukupally SR
Br J Ophthalmol; 2015 Sep; 99(9):1190-5. PubMed ID: 25740805
[TBL] [Abstract][Full Text] [Related]
17. Effect of topical application of terbinafine on fungal keratitis.
Liang QF; Jin XY; Wang XL; Sun XG
Chin Med J (Engl); 2009 Aug; 122(16):1884-8. PubMed ID: 19781365
[TBL] [Abstract][Full Text] [Related]
18. Natamycin versus natamycin combined with voriconazole in the treatment of fungal keratitis.
Cai J; Yang C; Wei Q; Lian H; An L; Zhang R
Pak J Med Sci; 2023; 39(3):775-779. PubMed ID: 37250561
[TBL] [Abstract][Full Text] [Related]
19. Improved Topical Ophthalmic Natamycin Suspension for the Treatment of Fungal Keratitis.
Cai C; Youssef AAA; Joshi PH; Varner C; Dudhipala N; Majumdar S
J Ocul Pharmacol Ther; 2024; 40(1):67-77. PubMed ID: 38117668
[No Abstract] [Full Text] [Related]
20. Topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in Nepal: rationale and design of a randomised controlled non-inferiority trial.
Hoffman JJ; Yadav R; Das Sanyam S; Chaudhary P; Roshan A; Singh SK; Arunga S; Matayan E; Macleod D; Weiss HA; Leck A; Hu V; Burton MJ
BMJ Open; 2020 Sep; 10(9):e038066. PubMed ID: 32998924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
